Cullinan Therapeutics (CGEM) Asset Writedowns and Impairment (2023)
Cullinan Therapeutics' (CGEM) quarterly Asset Writedowns and Impairment came in at $400000.0 in Q3 2023.
Cullinan Therapeutics (CGEM) Asset Writedowns and Impairment (2023) Analysis & Trends
Cullinan Therapeutics' Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $400000.0 for Q3 2023.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $400000.0 in Q3 2023; TTM through Dec 2024 was $400000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $440000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment steadied at $400000.0 in Q3 2023 per CGEM's latest filing.
- Across five years, Asset Writedowns and Impairment topped out at $400000.0 in Q3 2023 and bottomed at $400000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Cullinan Therapeutics | 368.65 Mn | 368.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 400,000.00 |
| Sep 30, 2023 | 400,000.00 |